Laboratory of Prof. Massimiliano Pagani at IFOM (the AIRC Institute of Molecular Oncology) and Macomics to bring together expertise on T-cell biology, ex-vivo tumoroids and macrophagesThe collaboration will combine advanced human ex vivo models with new therapeutic approaches to support Macomics’ continued exploration of novel macrophage biology EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom and MILAN, Italy, May 13, 2024 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered a scientific collaboration with Prof.

IFOM（AIRC分子肿瘤学研究所）和Macomics的Massimiliano Pagani教授的实验室汇集了T细胞生物学，离体类肿瘤和巨噬细胞方面的专业知识。该合作将将先进的人体离体模型与新的治疗方法相结合，以支持Macomics继续探索新型巨噬细胞生物学，英国爱丁堡和英国剑桥以及意大利米兰，2024年5月13日（环球通讯社）——Macomics Ltd，巨噬细胞药物发现的领导者，宣布它已经与教授进行了科学合作。

Massimiliano Pagani from the IFOM (the AIRC Institute of Molecular Oncology), one of Italy’s leading research institutes in Cancer Research. IFOM is focused on the study of cancer formation and development at the molecular level. Prof. Pagani’s laboratory is pioneering studies on Regulatory T cells in the tumour microenvironment.

来自IFOM（AIRC分子肿瘤学研究所）的Massimiliano Pagani是意大利癌症研究领域的领先研究机构之一。IFOM专注于在分子水平上研究癌症的形成和发展。帕加尼教授的实验室是对肿瘤微环境中调节性T细胞的开创性研究。

The collaboration will see Macomics work with Dr Francesca Simoncello in Prof. Pagani’s lab to synergize this deep knowledge, particularly in the use of ex vivo tumoroids and T cell biology, with Macomics’ macrophage expertise. The goal is to explore new modes of action for macrophage targeted therapies.

这项合作将使Macomics在帕加尼教授的实验室与Francesca Simoncello博士合作，将这一深刻的知识与Macomics的巨噬细胞专业知识相结合，特别是在离体类肿瘤和T细胞生物学的使用方面。目标是探索巨噬细胞靶向治疗的新作用模式。

Macomics is exploiting the potential of macrophage-targeted approaches to develop first-in-class medicines to address disease of high unmet medical need. The company’s ENIGMAC macrophage drug discovery platform allows access to previously hidden disease specific macrophage targets: It integrates large volume human data sets, next generation human macrophage cell models, and proprietary macrophage genome editing capability to discover novel targets, unlock new disease biology, and de-risk clinical translation.

Macomics正在利用巨噬细胞靶向方法的潜力，开发一流的药物，以解决高度未满足医疗需求的疾病。该公司的ENIGMAC巨噬细胞药物发现平台允许访问以前隐藏的疾病特异性巨噬细胞靶标：它集成了大量人类数据集，下一代人类巨噬细胞模型和专有巨噬细胞基因组编辑功能，以发现新靶点，解锁新的疾病生物学，并降低临床翻译风险。

Under the collaboration the parties will explore together the potenti.

在合作下，双方将共同探索潜力。